Literature DB >> 26283614

A peculiar etiology of acute heart failure: adrenergic myocarditis.

Maria Vincenza Polito1, Amelia Ravera2, Angelo Silverio2, Costantina Prota2, Catello Lambiase2, Santo Dellegrottaglie3, Roberto Ascoli2, Rosario Farina2, Rodolfo Citro2, Federico Piscione4.   

Abstract

Pheochromocytoma can occur with a variety of cardiovascular signs and symptoms, and this tumor can also precipitate an acute heart failure associated with the typical clinical and instrumental findings of myocarditis. This peculiar etiology of acute myocarditis, known as “adrenergic myocarditis,” should be suspected when specific “red flags” of pheochromocytoma such as headache, palpitations, diaphoresis, hypertension, orthostatic hypotension, and left ventricular dysfunction suggesting Takotsubo syndrome are detected. In fact, its diagnosis allows a specific targeted therapy.

Entities:  

Mesh:

Year:  2015        PMID: 26283614     DOI: 10.1016/j.ajem.2015.07.025

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  3 in total

1.  Adrenergic Shock Presenting with Atypical Takotsubo Syndrome: The Alliance Between Levosimendan and Intraaortic Balloon Pump Against the Pheochromocytoma.

Authors:  Maria Vincenza Polito; Elena De Angelis; Andreas Hagendorff; Alessandro Puzziello; Francesco Vigorito; Amelia Ravera
Journal:  Anatol J Cardiol       Date:  2022-04       Impact factor: 1.475

2.  Reply to Letter to the Editor: "Pheochromocytoma and Takotsubo Syndrome: An Ominous Duo".

Authors:  Maria Vincenza Polito; Elena De Angelis; Amelia Ravera
Journal:  Anatol J Cardiol       Date:  2022-08       Impact factor: 1.475

3.  Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With 177Lu-DOTATATE: A Case Report.

Authors:  Alexis Huot Daneault; Mélanie Desaulniers; Jean-Mathieu Beauregard; Alexis Beaulieu; Frédéric Arsenault; Geneviève April; Éric Turcotte; François-Alexandre Buteau
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-22       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.